Prediction of response to kinase inhibitors based on protein phosphorylation profiles in tumor tissue from advanced renal cell cancer patients

Trial Profile

Prediction of response to kinase inhibitors based on protein phosphorylation profiles in tumor tissue from advanced renal cell cancer patients

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 22 Aug 2013

At a glance

  • Drugs Axitinib (Primary) ; Everolimus (Primary) ; Pazopanib (Primary) ; Sorafenib (Primary) ; Sunitinib (Primary)
  • Indications Renal cancer
  • Focus Biomarker; Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 01 Dec 2012 Lead trial centre added as reported by Netherlands Trial Register record.
    • 01 Dec 2012 New source identified and integrated (Netherlands Trial Register: NTR3710).
    • 05 Jul 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top